Streetbeat News

Stock Prices

HAS

Analysts have mixed views on Hasbro (NASDAQ:HAS) with recent ratings showing a slight bullish trend. The average 12-month price target has increased to $78.43. Despite a decline in revenue growth, Hasbro maintains strong profitability and financial health, though its debt-to-equity ratio is a concern.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 12:01 pm

HUMA

Humacyte, Inc. (NASDAQ:HUMA) will present a late-breaking abstract on its V007 Phase 3 clinical trial at the American Society of Nephrology's Kidney Week 2024. The trial involves the acellular tissue engineered vessel (ATEV™) for arteriovenous access in end-stage renal disease patients.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 12:01 pm

BPTH

DOCU

SAGE

Bio-Path Holdings has launched a new therapeutic program using DNAbilize technology for obesity, marking its first non-cancer application. DocuSign shares rise as it joins the S&P MidCap 400. Sage Therapeutics shares fall after halting Alzheimer's drug development due to poor Phase 2 results.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 12:01 pm

EPAM

EPAM Systems (NYSE:EPAM) has received mixed analyst ratings over the past three months, with a slight increase in the average 12-month price target to $232.56. Analysts have varied in their recommendations, with some raising their price targets and others maintaining or lowering them. EPAM faces revenue challenges but maintains strong net margins and asset utilization.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 12:01 pm

SEDG

SolarEdge Technologies (NASDAQ:SEDG) has received mixed analyst reviews over the past three months, with a majority of analysts being indifferent. The average 12-month price target has declined by 23.49%. Analysts have adjusted their ratings and price targets, reflecting a cautious outlook on the company's performance. SolarEdge faces challenges with revenue growth, net margin, ROE, and ROA, but maintains a sound debt management structure.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 12:00 pm

QCOM

Analysts have varied ratings for Qualcomm (NASDAQ:QCOM), ranging from bullish to bearish. The average 12-month price target has increased by 9.87% to $211.25. Recent analyst actions include both raises and lowers in ratings and price targets, reflecting changing market conditions and company performance. Qualcomm shows strong financial metrics, including a net margin of 22.67% and ROE of 8.67%, but faces challenges with a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 12:00 pm

TTEK

Tetra Tech shares rose following KeyBanc's decision to maintain an Overweight rating and increase the price target from $49 to $56.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 11:51 am

QCOM

Qualcomm's stock is experiencing a decline following a downgrade by KeyBanc from Overweight to Sector Weight.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 11:51 am

DOCU

DocuSign shares are experiencing an upward trend following the announcement that the company will be included in the S&P MidCap 400 index.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 11:51 am

PEP

PepsiCo reported mixed Q3 results with a slight revenue decline and lowered its 2024 revenue guidance. Despite challenges, the company maintained profitability through cost controls. PepsiCo expects a low single-digit increase in organic revenue and at least 8% EPS growth for 2024.

Portfolio Pulse from Akanksha Bakshi

October 08, 2024 | 11:28 am